The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats #
Abstract
Portal hypertension, the most important complication in patients with cirrhosis of the liver, is a serious and life-threatening disease for which there are few therapeutic options. Because angiogenesis is a pathological hallmark of portal hypertension, the goal of this study was to determine the effects of sorafenib—a potent inhibitor of proangiogenic vascular endothelial growth factor receptor 2 (VEGFR-2), platelet-derived growth factor receptor β (PDGFR-β), and Raf kinases—on splanchnic, intrahepatic, systemic, and portosystemic collateral circulations in two different experimental models of portal hypertension: rats with prehepatic portal hypertension induced by partial portal vein ligation and rats with intrahepatic portal hypertension and secondary biliary cirrhosis induced by bile duct ligation. Such a comprehensive approach is necessary for any translational research directed toward defining the efficacy and potential clinical application of new therapeutic agents. Sorafenib administered orally once a day for 2 weeks in experimental models of portal hypertension and cirrhosis effectively inhibited VEGF, PDGF, and Raf signaling pathways, and produced several protective effects by inducing an approximately 80% decrease in splanchnic neovascularization and a marked attenuation of hyperdynamic splanchnic and systemic circulations, as well as a significant 18% decrease in the extent of portosystemic collaterals. In cirrhotic rats, sorafenib treatment also resulted in a 25% reduction in portal pressure, as well as a remarkable improvement in liver damage and intrahepatic fibrosis, inflammation, and angiogenesis. Notably, beneficial effects of sorafenib against tissue damage and inflammation were also observed in splanchnic organs. Conclusion: Taking into account the limitations of translating animal study results into humans, we believe that our findings will stimulate consideration of sorafenib as an effective therapeutic agent in patients suffering from advanced portal hypertension. (Hepatology 2009.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Bataller, R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200524282c1 · Cited by 1,472
Blood Vessel Formation: What Is Its Molecular Basis?
Folkman, J., & D'Amore, P. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81810-3 · Cited by 1,215
Eberhard, A., Kahlert, S., Goede, V., Hemmerlein, B., Plate, K. H., & Augustin, H. G. (2000) · PubMed · Cited by 753
Abraldes, J. G., Tarantino, I., Turnes, J., Garcia-Pagan, J. C., Rodés, J., & Bosch, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50133 · Cited by 529
Self-citationD’Amico, G., Garcia-Pagan, J. C., Luca, A., & Bosch, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.09.013 · Cited by 512
Self-citationPinzani, M., Gesualdo, L., Sabbah, G. M., & Abboud, H. E. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114363 · Cited by 478
The paradox of nitric oxide in cirrhosis and portal hypertension: Too much, not enough
Wiest, R., & Groszmann, R. J. (2002) · Hepatology · doi:10.1053/jhep.2002.31432 · Cited by 471
PATHOPHYSIOLOGY OF PORTAL HYPERTENSION
Bosch, J., Pizcueta, P., Feu, F., Fernández, M., & García-Pagán, J. C. (1992) · Gastroenterology Clinics of North America · doi:10.1016/s0889-8553(21)00175-8 · Cited by 307
Self-citationTugues, S., Fernandez-Varo, G., Muñoz-Luque, J., Ros, J., Arroyo, V., Rodés, J., Friedman, S. L., Carmeliet, P., Jiménez, W., & Morales-Ruiz, M. (2007) · Hepatology · doi:10.1002/hep.21921 · Cited by 261
Fernandez, M., Vizzutti, F., Garcia-Pagan, J. C., Rodes, J., & Bosch, J. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.12.012 · Cited by 259
Self-citationBiologic significance of angiopoietin-2 expression in human hepatocellular carcinoma
Tanaka, S., Mori, M., Sakamoto, Y., Makuuchi, M., Sugimachi, K., & Wands, J. R. (1999) · Journal of Clinical Investigation · doi:10.1172/jci4891 · Cited by 256
Interleukin 1, interleukin 6 and tumor necrosis factor in infection, inflammation and immunity
Bendtzen, K. (1988) · Immunology Letters · doi:10.1016/0165-2478(88)90141-1 · Cited by 245
Sinusoidal remodeling and angiogenesis: A new function for the liver-specific pericyte?
Lee, J. S., Semela, D., Iredale, J., & Shah, V. H. (2007) · Hepatology · doi:10.1002/hep.21564 · Cited by 237
Fernandez, M., Mejias, M., Angermayr, B., Garcia-Pagan, J. C., Rodés, J., & Bosch, J. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.02.022 · Cited by 217
Self-citationFernandez, M., Mejias, M., Garcia-Pras, E., Mendez, R., Garcia-Pagan, J. C., & Bosch, J. (2007) · Hepatology · doi:10.1002/hep.21785 · Cited by 177
Self-citationBacterial Translocation in Acute and Chronic Portal Hypertension
Quigley, E. M. M., & Garcia-Tsao, G. (1994) · Hepatology · doi:10.1002/hep.1840200145 · Cited by 165
Semela, D., Das, A., Langer, D., Kang, N., Leof, E. B., & Shah, V. H. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.04.010 · Cited by 141
Bacterial translocation in acute and chronic portal hypertension
García–Tsao, G., Albillos, A., Barden, G. E., & West, B. A. (1993) · Hepatology · doi:10.1002/hep.1840170622 · Cited by 141
Neef, M., Ledermann, M., Saegesser, H., Schneider, V., & Reichen, J. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.07.030 · Cited by 140
Fernández, M., García‐Pagán, J. C., Casadevall, M., Bernadich, C., Piera, C., Whittle, B. J. R., Piqué, J. M., Bosch, J., & Rodés, J. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90698-3 · Cited by 125
Self-citationPortal Hypertension After Bile Duct Obstruction
Franco, D. (1979) · Archives of Surgery · doi:10.1001/archsurg.1979.01370330086016 · Cited by 116
Albillos, A., de-la-Hera, A., & Álvarez‐Mon, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16206-5 · Cited by 98
Angermayr, B., Mejías, M., Gracia‐Sancho, J., García‐Pagán, J. C., Bosch, J., & Fernández, M. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.09.021 · Cited by 80
Self-citationHow to Prevent Varices From Bleeding: Shades of Grey—The Case for Nonselective β Blockers
Thalheimer, U., Bosch, J., & Burroughs, A. K. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.10.028 · Cited by 80
Self-citationBiecker, E., Gottardi, A. D., Neef, M., Unternährer, M., Schneider, V., Ledermann, M., Sägesser, H., Shaw, S., & Reichen, J. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.079616 · Cited by 78
Angermayr, B., Fernández, M., Mejías, M., Gracia‐Sancho, J., García‐Pagán, J. C., & Bosch, J. (2006) · Gut · doi:10.1136/gut.2005.088013 · Cited by 60
Self-citationVascular density and VEGF expression in hepatic lesions.
Brodsky, S. V., Mendelev, N., Melamed, M. R., & Ramaswamy, G. (2007) · PubMed · Cited by 60
Medina, J. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00053-9 · Cited by 56
Navasa, M., Forns, X., Sánchez, V., Andreu, H., Marcos, V., Boarràs, J. M., Rimola, A., Grande, L., García-Valdecasas, J. C., Granados, A., et al. (1996) · Journal of Hepatology · doi:10.1016/s0168-8278(96)80064-x · Cited by 53
Xu, H., Shi, B., Lü, X., Liang, F., Jin, X., Tai-huang, W., & Xu, J. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.2349 · Cited by 27
Cited by
Molecular and cellular mechanisms of liver fibrosis and its regression
Kisseleva, T., & Brenner, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00372-7 · Cited by 2,024
Management of Varices and Variceal Hemorrhage in Cirrhosis
Garcia-Tsao, G., & Bosch, J. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0901512 · Cited by 951
Self-citationRole of the Microenvironment in the Pathogenesis and Treatment of Hepatocellular Carcinoma
Hernandez–Gea, V., Toffanin, S., Friedman, S. L., & Llovet, J. M. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.002 · Cited by 722
Garcia‐Tsao, G., Friedman, S., Iredale, J., & Pinzani, M. (2010) · Hepatology · doi:10.1002/hep.23478 · Cited by 538
Targeted Therapies for Hepatocellular Carcinoma
Villanueva, A., & Llovet, J. M. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.03.006 · Cited by 449
Metadata
- Authors
- Mejias, M., Garcia-Pras, E., Tiani, C., Miquel, R., Bosch, J., & Fernandez, M.
- Venue
- Hepatology
- Published
- 2009-04
- Volume
- 49
- Issue
- 4
- Pages
- 1245-1256
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2162226128
- Cited by
- 293
- References
- 35
- FWCI
- 12.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.